Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Phytother Res ; 36(9): 3505-3528, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-35858779

RESUMO

Phytolaccaceae is a plant family of the order Caryophyllales, which includes species used in traditional medicine to treat diseases. The purpose of this study was to investigate Phytolaccaceae family plants with potential antimicrobial action, through a systematic review. The study was conducted following the criteria of PRISMA protocol. The search was performed in the electronic databases PubMed, Web of Science, Scopus, and LILACS, in March 2021. The search strategy used free descriptors and terms, limiting articles to the English language, regardless of publication year. The risk of bias and the quality of publications were based on the CONSORT checklist, modified for in vitro studies and SYRCLE's RoB tool for in vivo study. Five independent judges performed quality assessments of publications and risk of bias analysis. Ninety-five publications were retrieved from the databases and, after screening and eligibility criteria, 22 articles remained, from 1998 to 2019. In the selected studies, the plants were obtained from eight countries. In vivo and in vitro studies of extracts from the Phytolaccaceae family plants, evaluating antibacterial (8 publications), antifungal (8), anti-Trypanosoma (2), anti-Leishmania (2), antiviral (1), and antiamoebic (1) activities, are included. The plant species identified belong to genera Petiveria, Phytolacca, Gallesia, Trichostigma, and Seguieria. The risk of bias in the 22 publications both in vitro and in vitro was suboptimal. The evidence obtained showed that the Phytolaccaceae family, a source of plants with antimicrobial action, can serve as a basis for the creation of new herbal medicines, expanding the possibility of treatment for infectious diseases and stimulating their preservation and biodiversity. However, more high-quality studies are needed to establish the clinical efficacy of the plant.


Assuntos
Phytolaccaceae , Plantas Medicinais , Antifúngicos/uso terapêutico , Medicina Tradicional , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico
2.
Tuberculosis (Edinb) ; 148: 102545, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39079220

RESUMO

PURPOSE: This study target the synthesis of 22 salicylhydrazones derivatives to apply in vitro screening to explore their potential in the search for new anti-TB prototypes drugs. METHODS: The minimum inhibitory concentration (MIC) were evaluated against Mycobacterium tuberculosis (Mtb) H37Rv and clinical isolates. Drug combination assay, cytotoxicity assay, ethidium bromide accumulation assay (EtBr) and in silico analysis regarding the absorption, distribution, metabolism, excretion and toxicity (ADMET) and pharmacological properties were also performed. RESULTS: Three most promising compounds were selected (10, 11 and 18) to proceed with screening tests. Compound 18 presented the lowest MIC value (0.49 µg/mL) against Mtb H37Rv strain, followed by compounds 11 (3.9 µg/mL) and 10 (7.8 µg/mL). All compounds showed activity against drug susceptible and resistant clinical isolates. Cytotoxicity results were promising for all salicylhydrazones, with SI values up to 4,205 for compound 18. The derivative 10 was the only one that demonstrated a non-promising cytotoxicity scenario for a single cell line. All derivatives showed an additive effect (FICI >0.5 to 4.0) in combination with isoniazid, ethambutol and rifampicin. CONCLUSION: All salicylhydrazones showed potential in the screening tests performed in this study and compound 18 stood out due to its activity against susceptible and resistant bacilli at low concentrations and low cytotoxicity.


Assuntos
Antituberculosos , Hidrazonas , Testes de Sensibilidade Microbiana , Mycobacterium tuberculosis , Antituberculosos/farmacologia , Mycobacterium tuberculosis/efeitos dos fármacos , Hidrazonas/farmacologia , Hidrazonas/síntese química , Humanos , Avaliação Pré-Clínica de Medicamentos/métodos , Relação Estrutura-Atividade , Animais
3.
Future Microbiol ; : 1-13, 2024 Oct 03.
Artigo em Inglês | MEDLINE | ID: mdl-39360625

RESUMO

Aim: Tuberculous meningitis (TBM) is one of the most severe clinical forms of tuberculosis (TB). Since epidemiological studies can contribute to TB control, we conducted a review and meta-analysis of epidemiological publications of adults TBM cases in countries with high incidence of TB.Materials & methods: The search resulted in 11,855 articles, in which 21 ultimately were included in our review and 15 in our meta-analysis.Results: TBM mortality was 25% with death rates of 70% in Africa. The review showed different and non-concordant diagnostic techniques and treatment schemes.Conclusion: Adults living in the African region are at high risk of death from TBM, highlighting an urgent need of guidelines to support diagnosis and treatment, and ultimately, to reduce mortality.


Tuberculosis (TB) is a disease that mostly affects the lungs. It can also affect other organs. When TB affects the brain and spinal cord, it is called tuberculous meningitis (TBM). We looked to analyze the traits of the adults with TBM that live in countries with a high number of cases of TB. We searched scientific publications that studied these populations to find information that may help to control the disease. The death rate of TBM was 25%, reaching up to 70% in Africa. We found some disparities regarding diagnosis and treatment. Adults living in Africa have a higher risk of dying from TBM. We need guidelines about the diagnosis and treatment of TBM to help reduce TBM deaths in these countries.

4.
Future Microbiol ; 19(17): 1445-1454, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39258398

RESUMO

Aim: Polymyxin B (PMB) is one of the few therapeutic options for treating infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB). However, the emergence of PMB-resistant CR-GNB strains has prompted the exploration of antibiotic adjuvants as potential therapeutic avenues. Thus, this study evaluates the potential of 3,5-dinitrobenzoic acid derivatives (DNH01, DNH11, DNH13 and DNH20) and isoniazid-N-acylhydrazones (INZ1-7, INZ9 and INZ11) as adjuvants to enhance PMB efficacy against CR-GNB.Materials & methods: MIC, MBC and drug combination assays were conducted using multidrug-resistant clinical isolates of Enterobacterales and Acinetobacter baumannii. In addition, the effects of PMB and PMB + DNH derivatives were assessed through flow cytometry and scanning electron microscopy (SEM).Results: DNH01, DNH11 and DNH20, unlike the INH-acylhydrazones, significantly restored PMB activity (MIC ≤ 2 µg/ml) in 80% of the tested isolates. Flow cytometry and SEM assays confirmed that DNH derivatives rescued the activity of PMB, yielding results comparable to those expected for PMB alone but at 256-fold lower concentrations.Conclusion: These findings suggest DNH derivatives hold substantial promise as PMB adjuvants to combat PMB-resistant CR-GNB infections.


[Box: see text].


Assuntos
Antibacterianos , Carbapenêmicos , Bactérias Gram-Negativas , Testes de Sensibilidade Microbiana , Polimixina B , Polimixina B/farmacologia , Antibacterianos/farmacologia , Bactérias Gram-Negativas/efeitos dos fármacos , Carbapenêmicos/farmacologia , Humanos , Acinetobacter baumannii/efeitos dos fármacos , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Adjuvantes Farmacêuticos/farmacologia , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Infecções por Bactérias Gram-Negativas/microbiologia , Sinergismo Farmacológico
5.
Future Med Chem ; 15(24): 2239-2255, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-38014535

RESUMO

Background: Paracoccidioidomycosis (PCM) is a systemic infection caused by Paracoccidioides spp. (Pb). PCM can be associated or clinically confused with tuberculosis (TB), another pulmonary infection, caused by Mycobacterium tuberculosis (Mtb). Futhermore, the long treatment time of TB and PCM and the cases of TB drug resistance impose difficulties for the cure of these diseases. Results: New 1,3,4-oxadiazoles containing the 4-methoxynaphthalene ring were synthesized and their antimicrobial activity was evaluated against Pb and Mtb. The derivative 6n (with 2-hydroxy-5-nitrophenyl subunit) is the most promising of the series. Conclusion: The 1,3,4-oxadiazole 6n can be used as a prototype drug candidate, with anti-Pb and anti-MTb activities, showing a broad-spectrum profile for the treatment of both pulmonary infections.


Assuntos
Anti-Infecciosos , Mycobacterium tuberculosis , Paracoccidioidomicose , Tuberculose , Humanos , Oxidiazóis/farmacologia , Chumbo/uso terapêutico , Tuberculose/tratamento farmacológico , Paracoccidioidomicose/tratamento farmacológico , Paracoccidioidomicose/microbiologia , Anti-Infecciosos/farmacologia , Anti-Infecciosos/uso terapêutico
6.
Future Microbiol ; 16: 1303-1308, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34743541

RESUMO

Background: Pyrazinamide (PZA) represents a milestone as a first-line antituberculosis drug due to its sterilizing activity against Mycobacterium tuberculosis. Materials & Methods: The protein changes induced by subinhibitory PZA exposure of M. tuberculosis in acidic pH were evaluated by a proteomic approach. Results: Among the 1059 M. tuberculosis proteins identified, the specific acidification in the culture medium induced the over-representation of MurF (Rv2157c), and its under-representation was induced by 12 h of PZA exposure. PanB (Rv2225) was over-represented at 24 h of PZA exposure. Conclusion: The authors highlight the over-representation of PanB in M. tuberculosis correlates of PZA action in acidic pH, reinforcing the role of the pantothenate pathway as a bacillus drug target to be explored.


Assuntos
Mycobacterium tuberculosis , Tuberculose , Antituberculosos/farmacologia , Farmacorresistência Bacteriana , Humanos , Testes de Sensibilidade Microbiana , Mycobacterium tuberculosis/metabolismo , Proteômica , Pirazinamida/farmacologia , Tuberculose/tratamento farmacológico , Tuberculose/microbiologia
7.
Infect Disord Drug Targets ; 19(1): 73-80, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-29366429

RESUMO

BACKGROUND: In recent years, very few effective drugs against Mycobacterium tuberculosis have emerged, which motivates the research with drugs already used in the treatment of tuberculosis. Ethambutol is a bacteriostatic drug that affects cell wall integrity, but the effects of this drug on bacilli are not fully exploited. OBJECTIVE: Based on the need to better investigate the complex mechanism of action of ethambutol, our study presented the proteome profile of M. tuberculosis after different times of ethambutol exposure, aiming to comprehend the dynamics of bacilli response to its effects. M. tuberculosis was exposed to ½ MIC of ethambutol at 24 and 48 hours. The proteins were identified by MALDI-TOF/TOF. RESULTS: The main protein changes occurred in metabolic proteins as dihydrolipoyl dehydrogenase (Rv0462), glutamine synthetase1 (Rv2220), electron transfer flavoprotein subunit beta (Rv3029c) and adenosylhomocysteinase (Rv3248c). CONCLUSION: Considering the functions of these proteins, our results support that the intermediary metabolism and respiration were affected by ethambutol and this disturbance provided proteins that could be explored as additional targets for this drug.


Assuntos
Antituberculosos/farmacologia , Proteínas de Bactérias/metabolismo , Etambutol/farmacologia , Mycobacterium tuberculosis/efeitos dos fármacos , Tuberculose/tratamento farmacológico , Antituberculosos/uso terapêutico , Parede Celular/efeitos dos fármacos , Etambutol/uso terapêutico , Humanos , Redes e Vias Metabólicas/efeitos dos fármacos , Testes de Sensibilidade Microbiana/métodos , Mycobacterium tuberculosis/metabolismo , Proteoma/efeitos dos fármacos , Proteoma/isolamento & purificação , Fatores de Tempo , Tuberculose/microbiologia
8.
Tuberculosis (Edinb) ; 104: 24-29, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28454646

RESUMO

BACKGROUND: Linezolid (LZD) is not commonly used for treating tuberculosis (TB), but in some patients with drug-resistant TB it is being used. However, the in vitro LZD activity, in combination with rifampicin (RIF) against Mycobacterium tuberculosis has not been fully elucidated. AIMS: The aim of this study was to evaluate the in vitro activity of RIF/LZD combination against M. tuberculosis clinical isolates. MATERIALS AND METHODS: The activity of the RIF/LZD combination was firstly determined in M. tuberculosis H37Rv, 14 susceptible, 9 isoniazid nonresistant and 14 multi-drug resistant (MDR) M. tuberculosis clinical isolates by modified checkerboard assay, Resazurin Drugs Combination Microtiter Assay (REDCA). After, the Time Kill Curve Assay, at 0.5 × MIC of drugs, in combination and alone, was performed in M. tuberculosis H37Rv and 8 (20.5%) of those clinical isolates, which the RIF/LZD combination showed to have synergistic effect by the checkerboard assay. RESULTS AND CONCLUSION: By Time Kill Curve Assay, we could observe in M. tuberculosis H37Rv and susceptible isolates, that LZD alone, at sub inhibitory concentration, has poor effect on the bacillus death. In some cases, the bacillus growth stayed constant while in others showed regrowth at the eighth day of drug exposure. RIF alone exhibits potent concentration-dependent bactericidal activity, and was strongly dependent by the drug exposure time. The RIF/LZD combination accomplished a bacteriostatic effect in the reference strain and susceptible isolates. For the RIF resistant isolates, the RIF/LZD combination did not enhance the effect in killing bacillus. In this sense, additional, in vitro and in vivo studies are needed to evaluate the effect of RIF/LZD combination in order to better understand the adjunctive action of LZD in the treatment of TB and prevent the emergence of mutants with resistance to the available anti-TB drugs.


Assuntos
Antituberculosos/farmacologia , Linezolida/farmacologia , Mycobacterium tuberculosis/efeitos dos fármacos , Rifampina/farmacologia , Farmacorresistência Bacteriana Múltipla , Sinergismo Farmacológico , Quimioterapia Combinada , Genótipo , Testes de Sensibilidade Microbiana , Viabilidade Microbiana/efeitos dos fármacos , Mycobacterium tuberculosis/genética , Mycobacterium tuberculosis/crescimento & desenvolvimento , Fatores de Tempo
9.
J Mol Model ; 23(4): 121, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28303436

RESUMO

The current multidrug therapy for tuberculosis (TB) is based on the use of isoniazid (INH) in combination with other antibiotics such as rifampin, ethambutol and pyrazinamide. Literature reports have shown that Mycobacterium tuberculosis, the causative agent of TB, has become resistant to this treatment by means of point mutations in the target enzymes of these drugs, such as catalase-peroxidase (KatG). By means of equilibrium molecular dynamics in the presence of the ligand, this work evaluated ten point mutations described in the enzyme KatG that are related to resistance to INH . The results showed that the resistance mechanism is related to stereochemical modifications at the N-terminal domain of the protein, which restrict INH access to its catalytic site, not involving mechanisms of electrostatic nature. These results show insights that can be useful for the identification of new anti-TB drugs which may be able to circumvent this mechanism of resistance.


Assuntos
Proteínas de Bactérias/genética , Catalase/genética , Farmacorresistência Bacteriana , Isoniazida/farmacologia , Simulação de Dinâmica Molecular , Mutação , Mycobacterium tuberculosis/enzimologia , Antituberculosos/farmacologia , Proteínas de Bactérias/antagonistas & inibidores , Catalase/antagonistas & inibidores , Domínio Catalítico , Ligantes , Mycobacterium tuberculosis/efeitos dos fármacos
10.
J Microbiol Methods ; 111: 119-21, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25683207

RESUMO

The susceptibility of rapidly growing mycobacteria (RGM) to linezolid and ciprofloxacin was evaluated by using resazurin as a growth indicator. The assay with resazurin supplemented medium performed as well as its addition to the medium at reading time and was efficient for the determination for the susceptibility profile in RGM.


Assuntos
Antibacterianos/farmacologia , Testes de Sensibilidade Microbiana/métodos , Micobactérias não Tuberculosas/efeitos dos fármacos , Micobactérias não Tuberculosas/crescimento & desenvolvimento , Oxazinas/metabolismo , Xantenos/metabolismo , Ciprofloxacina/farmacologia , Linezolida/farmacologia , Micobactérias não Tuberculosas/metabolismo
11.
PLoS One ; 10(4): e0123988, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25881083

RESUMO

Group B streptococcus (GBS), which commonly colonizes the female genital tract and rectum, can cause infections in newborns with varying severity, possibly leading to death. The aim of the present study was to evaluate Hitchens-Pike-Todd-Hewitt (HPTH) medium performance for GBS screening in pregnant women. A descriptive analytical cross-sectional study was performed with 556 pregnant women, of which 496 were at 35-37 weeks of gestation and 60 were at ≥ 38 weeks of gestation. The study was conducted from September 2011 to March 2014 in northern Paraná, Brazil. Vaginal and anorectal clinical specimens from each pregnant woman were plated on sheep blood agar (SBA) and seeded on HPTH medium and Todd-Hewitt enrichment broth. Of the 496 pregnant women at 35-37 weeks of gestation, 141 (28.4%) were positive for GBS, based on the combination of the three culture media and clinical specimens. The GBS colonization rates that were detected by each medium were 22.2% for HPTH medium, 21.2% for SBA, and 13.1% for Todd-Hewitt enrichment broth. Of the 60 pregnant women at ≥ 38 weeks of gestation, seven (11.7%) were positive for GBS. These results demonstrate that HPTH medium and SBA were more sensitive than Todd-Hewitt enrichment broth for GBS screening in pregnant women and good GBS recovery in culture, indicating that the two media should be used together for vaginal and anorectal specimens.


Assuntos
Canal Anal/microbiologia , Portador Sadio/microbiologia , Meios de Cultura/farmacologia , Programas de Rastreamento/métodos , Reto/microbiologia , Infecções Estreptocócicas/transmissão , Streptococcus agalactiae/isolamento & purificação , Vagina/microbiologia , Técnicas Bacteriológicas , Estudos Transversais , Feminino , Idade Gestacional , Humanos , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Gravidez , Manejo de Espécimes , Infecções Estreptocócicas/prevenção & controle , Streptococcus agalactiae/efeitos dos fármacos , Streptococcus agalactiae/crescimento & desenvolvimento
12.
IDCases ; 1(3): 60-2, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-26955529

RESUMO

This case report alerts to the existence of atypical forms of cutaneous leishmaniasis (CL). A woman with nodular cutaneous lesions over a neck with papules and pustules located deep in the hypodermis that formed plaques with subcutaneous induration and satellite papules was confirmed to have CL. After confirmation, the patient was treated with remission of the lesions, scarring and thickening of the skin.

13.
Ann Clin Lab Sci ; 39(4): 405-8, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19880770

RESUMO

This work describes a case of Haemophilus influenzae serotype a meningitis in Brazil, after almost a decade since the introduction of Haemophilus influenzae serotype b conjugate vaccine. Uncertainty about the replacement of H. influenzae serotypes as a cause of invasive diseases justifies continuous surveillance, coupled with investigations of carriage rates and requirements of chemoprophylaxis in contact persons.


Assuntos
Haemophilus influenzae/classificação , Meningite por Haemophilus/epidemiologia , Brasil/epidemiologia , Feminino , Humanos , Lactente , Meningite por Haemophilus/líquido cefalorraquidiano , Meningite por Haemophilus/patologia , Sorotipagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA